Skip to main content

Table 1 Demographic and clinical characteristics of the analysable population

From: An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France

 

Children

(N = 203)

Adults

(N = 280)

Total

(N = 483)

Gender (n,%; male)

129 (63.5%)

139 (49.6%)

268 (55.5%)

Age (mean ± SD; years)

11.8 (3.4)

33.8 (10.9)

24.5 (13.9)

Smoker or ex-smoker (n, %)

3 (1.5%)

74 (26.4%)

77 (15.9%)

Living in an urban environment (n, %)

88 (43.3%)

167 (59.6%)

255 (52.8%)

Age at onset of allergic rhinitis (mean ± SD; years)

7.8 (3.3)

18.6 (9.9)

14.1 (9.5)

Allergic rhinitis with conjunctivitis (n, %)

170 (83.7%)

244 (87.1%)

414 (85.7%)

Other allergic conditions (n, %)

 None

90 (44.3%)

143 (51.1%)

233 (48.2%)

 Asthma

84 (41.4%)

96 (34.3%)

180 (37.3%)

 Eczema

32 (15.8%)

30 (10.7%)

62 (12.8%)

 Food allergy

14 (6.9%)

16 (5.7%)

30 (6.2%)

 Urticaria

6 (3.0%)

12 (4.3%)

18 (3.7%)

Other associated chronic disease

9 (4.4%)

20 (7.1%)

29 (6.0%)

Symptom frequencya (ARIA classification) (n, %)

 Intermittent

30 (14.8%)

34 (12.1%)

64 (13.3%)

 Persistent

173 (85.2%)

246 (87.9%)

419 (86.7%)

Allergy severitya (ARIA classification) (n, %)

 Mild

15 (7.4%)

4 (1.4%)

19 (3.9%)

 Moderate or severe

188 (92.6%)

276 (98.6%)

464 (96.1%)

Specific grass pollen allergy test performed (n, %)

203 (100.0%)

280 (100.0%)

483 (100.0%)

 Skin prick test

200 (98.5%)

279 (99.6%)

479 (99.2%)

 Anti-grass pollen IgE assay

113 (55.7%)

143 (51.1%)

256 (53.0%)

 Nasal irritation test

None

None

None

Maintenance treatment previously prescribeda (n, %)

156 (76.8)

209 (74.6%)

365 (75.6%)

 Systemic antihistamines

142 (70.0%)

195 (69.6%)

337 (69.8%)

 Topical decongestants and other preparations

62 (30.5%)

85 (30.4%)

147 (30.4%)

 Topical corticosteroids

62 (30.5%)

79 (28.2%)

141 (29.2%)

 Systemic decongestants and anti-allergic drugs

34 (16.7%)

41 (14.6%)

75 (15.5%)

 Inhaled sympathomimetic drugs

21 (10.3%)

12 (4.3%)

33 (6.8%)

 Other

13 (6.4%)

14 (5.0%)

27 (5.6%)

Acute treatment previously prescribeda (n, %)

101 (49.8%)

119 (42.5%)

220 (45.5%)

 Systemic antihistamines

41 (20.2%)

56 (20.0%)

97 (20.1%)

 Topical decongestants and other preparations

39 (19.2%)

37 (13.2%)

76 (15.7%)

 Topical corticosteroids

38 (18.7%)

27 (9.6%)

65 (13.5%)

 Systemic decongestants and anti-allergic drugs

42 (20.7%)

45 (16.1%)

87 (18.0%)

 Inhaled sympathomimetic drugs

26 (12.8%)

21 (7.5% %)

47 (9.7%)

  1. ARIA allergic rhinitis and its impact on asthma, SD standard deviation
  2. aFor the previous (2014) pollen season